Clinical trials reporting efficacy of PD-1/PD-L1 inhibitors in NSCLC patients with KEAP1 mutations and the effect of KEAP1 mutations on PD-L1 expression and TMB status. Here, KEAP1 is linked to non-small cell lung carcinoma.